The effect of Dexmedetomidine on myocardial protection in patients undergoing Mitral valve replacement/ repair

Evaluation of the effect of adding dexmedetomidine to del-Nido cardioplegia solution on myocardial protection in patients undergoing mitral valve replacement / repair

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210713051881N1

Enrollment

Registered

2021-11-03

Start date

2021-11-22

Completion date

Unknown

Last updated

2021-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Evaluation of the effect of adding dexmedetomidine to del-Nido cardioplegia solution on myocardial protection in patients undergoing mitral valve replacement / repair. Nonrheumatic mitral valve disorders

Interventions

Intervention 1: Intervention group:Intervention group: Before administering the cardioplegia solution, a vial of 200 µg / ml dexmedetomidine (in a 2 ml syringe labeled A) per 500 ml of Del-Nido cardio

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Candidate patients for mitral valve repair or replacement with ejection fraction above 40%

Exclusion criteria

Exclusion criteria: History of supraventricular dysrhythmias History of heart surgery Nephropathy following the use of contrast agent (CIN) Persistent respiratory problems Patients with a history of Stroke and TIA Patients with a history of Coagulopathy Use an intra-aortic balloon pump (IABP) before and during surgery Use vasopressor before surgery Patient dissatisfaction to participate in the study The presence of any pathological disorder leading to the release of inflammatory cytokines Cardiopulmonary arrest before, during and after surgery

Design outcomes

Primary

Measure	Time frame
Troponin I Assay. Timepoint: Before entering the operating room, In the first hour, 6 hours later, 12 hours later and 24 hours after entering the Intensive Care Unit. Method of measurement: Blood sample.;Creatinine kinease _MB Assay. Timepoint: Before entering the operating room, In the first hour, 6 hours later, 12 hours later and 24 hours after entering the Intensive Care Unit. Method of measurement: Blood sample.;The rate of urinary output. Timepoint: The first 6 hours, the first 12 hours and 24 hours after the operation. Method of measurement: By catheterization.	—

Measure

Time frame

Troponin I Assay. Timepoint: Before entering the operating room, In the first hour, 6 hours later, 12 hours later and 24 hours after entering the Intensive Care Unit. Method of measurement: Blood sample.;Creatinine kinease _MB Assay. Timepoint: Before entering the operating room, In the first hour, 6 hours later, 12 hours later and 24 hours after entering the Intensive Care Unit. Method of measurement: Blood sample.;The rate of urinary output. Timepoint: The first 6 hours, the first 12 hours and 24 hours after the operation. Method of measurement: By catheterization.

—

Secondary

Measure	Time frame
CRP level. Timepoint: Before surgery, 6 hours after entering the Intensive Care Unit, 12 hours after and 24 hours after entering the Intensive Care Unit. Method of measurement: Blood sample.;ESR level. Timepoint: Before surgery, 6 hours after entering the Intensive Care Unit, 12 hours after and 24 hours after entering the Intensive Care Unit. Method of measurement: Blood sample.;Inotropic Score. Timepoint: In the Intensive Care Unit. Method of measurement: Inotropic score = ([dopamine + dobutamine]×1) + (milrinone×15) + ([epinephrine + norepinephrine + isoproterenol]×100).	—

Measure

Time frame

CRP level. Timepoint: Before surgery, 6 hours after entering the Intensive Care Unit, 12 hours after and 24 hours after entering the Intensive Care Unit. Method of measurement: Blood sample.;ESR level. Timepoint: Before surgery, 6 hours after entering the Intensive Care Unit, 12 hours after and 24 hours after entering the Intensive Care Unit. Method of measurement: Blood sample.;Inotropic Score. Timepoint: In the Intensive Care Unit. Method of measurement: Inotropic score = ([dopamine + dobutamine]×1) + (milrinone×15) + ([epinephrine + norepinephrine + isoproterenol]×100).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactPedram Chahi

Mashhad University of Medical Sciences

chahip981@mums.ac.ir+98 51 3760 3653

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026